In a Phase I/II trial NCT03647163 the goal is to evaluate the safety and efficacy of VSV-IFNB-hNIS at a low dose (5 × 1010 TCID50) in patients with solid tumors resistant to standard therapy and at a higher dose (1.7 × 1011 TCID50) in combination with pembrolizumab in patients with head and neck squamous cell carcinoma (HNSCC) and NSCLC resistant to standard therapy and immunotherapy with anti-PD1/PDL1 antibodies. The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.